Zydus Lifesciences Announces Successful Clinical Development of Pembrolizumab Biosimilar FYB206 for USFDA Filing
Zydus Lifesciences has achieved a major milestone with its proposed Pembrolizumab biosimilar, FYB206. A pivotal pharmacokinetic (PK) study…